In adult patients with septic shock and high circulating endotoxin activity, does the use of polymyxin B hemoperfusion therapy significantly decrease 28-day mortality? Among patients with septic shock and high endotoxin activity, polymyxin B haemoperfusion treatment plus conventional medical therapy compared with sham treatment plus conventional medical therapy did not reduce mortality at 28 days. High endotoxin activity is associated with multi-organ failure and increased mortality in sepsis Previous studies assessing pharmacological therapies to reduce circulating endotoxins in sepsis have not shown benefit Selective adsorption of endotoxins via hemoperfusion has been studied previously but these studies were not specific to patients with high circulating endotoxin levels The EUPHRATES study enrolled only patients with high circulating endotoxin levels.

Read More